{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:17:43Z","timestamp":1790511463161,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":3563,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1038\/sj.jid.5700122","type":"journal-article","created":{"date-parts":[[2006,1,12]],"date-time":"2006-01-12T15:20:00Z","timestamp":1137079200000},"page":"575-583","source":"Crossref","is-referenced-by-count":100,"title":["CD25 Expression Is Correlated with Histological Grade and Response to Denileukin Diftitox in Cutaneous T-Cell Lymphoma"],"prefix":"10.1016","volume":"126","author":[{"given":"Rakhshandra","family":"Talpur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro J.","family":"Alencar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narin","family":"Apisarnthanarax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly L.","family":"Herne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Duvic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/sj.jid.5700122_bb0010","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2165\/00128071-200203030-00006","article-title":"Treatment of cutaneous T-cell lymphoma","volume":"3","author":"Apisarnthanarax","year":"2002","journal-title":"Am J Clin Dermatol"},{"key":"10.1038\/sj.jid.5700122_bb0015","doi-asserted-by":"crossref","first-page":"223","DOI":"10.7326\/0003-4819-93-2-223","article-title":"Prospective staging evaluation of patients with cutaneous T-cell lymphoma","volume":"93","author":"Bunn","year":"1980","journal-title":"Annals of Internal Medicine"},{"key":"10.1038\/sj.jid.5700122_bb0020","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0190-9622(99)70079-4","article-title":"Prognostic factor analysis in mycosis fungoides\/S\u00e9zary Syndrome","volume":"40","author":"Diamandidou","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1038\/sj.jid.5700122_bb0025","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1309\/YB79JG4TMJERQ7PV","article-title":"Primary Sezary syndrome commonly shows low-grade cytologic atypia, an absence of epidermotropism","volume":"123","author":"Diwan","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"10.1038\/sj.jid.5700122_bb0030","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is Efctive and safe for the treatment of refractory advanced stage cutaneous T cell lymphoma: multi-national phase II\u2013III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1038\/sj.jid.5700122_bb0035","first-page":"581","article-title":"Phase 2\u20133 clinical trial of oral targretin (bexarotene) capsules for the treatment of refractory or persistent early stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"issue":"Suppl 1","key":"10.1038\/sj.jid.5700122_bb0040","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.3816\/CLM.2000.s.005","article-title":"DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology","volume":"1","author":"Foss","year":"2000","journal-title":"Clin Lymphoma"},{"key":"10.1038\/sj.jid.5700122_bb0045","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3816\/CLM.2001.n.005","article-title":"Biological correlates of acute hypersensitivity events with DAB389IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedications","volume":"1","author":"Foss","year":"2001","journal-title":"Clin Lymphoma"},{"key":"10.1038\/sj.jid.5700122_bb0050","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood-2004-11-4570","article-title":"A phase 1 trial of boxarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"106","author":"Foss","year":"2005","journal-title":"Blood"},{"key":"10.1038\/sj.jid.5700122_bb0055","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0889-8588(03)00110-2","article-title":"Interleukin-2 receptor-directed therapies for cutaneous lymphomas","volume":"17","author":"Foss","year":"2003","journal-title":"Hematol Oncol Clin N Am"},{"key":"10.1038\/sj.jid.5700122_bb0060","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1001\/archderm.139.7.926-a","article-title":"Memorials and mandates for cutaneous lymphomas","volume":"139","author":"Heald","year":"2003","journal-title":"Arch. Dermatol."},{"key":"10.1038\/sj.jid.5700122_bb0065","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood.V89.1.32","article-title":"Association of erythrodermic cutaneous T cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor Vb gene expansion","volume":"89","author":"Jackow","year":"1997","journal-title":"Blood"},{"key":"10.1038\/sj.jid.5700122_bb0070","series-title":"World Health Organization Classification of tumors. Pathology and genetics of tumors of hematopoietic and lymphoid tissues","author":"Jaffe","year":"2001"},{"key":"10.1038\/sj.jid.5700122_bb0075","doi-asserted-by":"crossref","first-page":"ix","DOI":"10.1046\/j.1523-1747.2003.12458.x","article-title":"The current state and future of clonality studies in mycosis fungoides","volume":"121","author":"Jones","year":"2003","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1038\/sj.jid.5700122_bb0080","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1158\/1078-0432.CCR-0721-03","article-title":"CD25 expression in cutaneous T-cell lymphoma is dependent on tissue microenvironment: implications for targeted therapy","volume":"10","author":"Jones","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1038\/sj.jid.5700122_bb0085","first-page":"276","article-title":"Mycosis fungoides and the S\u00e9zary Syndrome","volume":"26","author":"Kim","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1038\/sj.jid.5700122_bb0090","doi-asserted-by":"crossref","first-page":"6539","DOI":"10.4049\/jimmunol.172.11.6539","article-title":"Promotion of allograft survival by CD4+CD25+ regulatory T cells: evidence for in vivo inhibition of effector cell proliferation","volume":"172","author":"Lee","year":"2004","journal-title":"J Immunol"},{"key":"10.1038\/sj.jid.5700122_bb0095","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1182\/blood.V79.10.2547.bloodjournal79102547","article-title":"Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor","volume":"79","author":"LeMaistre","year":"1992","journal-title":"Blood"},{"key":"10.1038\/sj.jid.5700122_bb0100","first-page":"399","article-title":"Phase I trial of a ligand fusion protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2","volume":"91","author":"LeMaistre","year":"1998","journal-title":"Blood"},{"key":"10.1038\/sj.jid.5700122_bb0105","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1084\/jem.172.6.1735","article-title":"Interferon gamma plays a critical role in induced cell death of effector T cell: a possible third mechanism of self-tolerance","volume":"172","author":"Lui","year":"1990","journal-title":"J Exp Med"},{"key":"10.1038\/sj.jid.5700122_bb0110","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1084\/jem.180.1.241","article-title":"Interleukin-2 receptor gamma chain expression on resting and activated lymphoid cells","volume":"180","author":"Nakarai","year":"1994","journal-title":"Exp. Med."},{"key":"10.1038\/sj.jid.5700122_bb0115","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","article-title":"Pivotal phase III trial of two dose levels of DAB389-IL2 (Ontak) for the treatment of cutaneous t cell lymphoma","volume":"19","author":"Olsen","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1038\/sj.jid.5700122_bb0120","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1182\/blood.V94.3.902.415k23_902_908","article-title":"Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses","volume":"94","author":"Rook","year":"1999","journal-title":"Blood"},{"key":"10.1038\/sj.jid.5700122_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00000372-199802000-00001","article-title":"Histologic and immunophenotypic features prior to transformation in patients with transformed cutaneous T-cell lymphoma; is CD25 expression in skin biopsy samples predictive of large cell transformation in cutaneous T-cell lymphoma","volume":"20","author":"Stefanato","year":"1998","journal-title":"Am J Dermatopathol."},{"key":"10.1038\/sj.jid.5700122_bb0130","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1001\/archderm.136.4.504","article-title":"Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients","volume":"136","author":"van Doorn","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1038\/sj.jid.5700122_bb0135","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2165\/00063030-200115070-00002","article-title":"Therapeutic advances in biological response modifiers in the treatment of cutaneous T-cell lymphoma","volume":"15","author":"Vittorio","year":"2001","journal-title":"BioDrugs"},{"key":"10.1038\/sj.jid.5700122_bb0140","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1067\/mjd.2002.118538","article-title":"Update on erythrodermic cutaneous T-cell lymphoma: Report on the International Society for Cutaneous Lymphomas","volume":"46","author":"Vonderheid","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1038\/sj.jid.5700122_bb0145","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1472-6890-2-5","article-title":"A stable aberrant immunophenotype characterizes nearly all cases of cutaneous T-cell lymphoma in blood and can be used to monitor response to therapy","volume":"10","author":"Washington","year":"2002","journal-title":"BMC Clin Pathol"},{"key":"10.1038\/sj.jid.5700122_bb0150","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/archderm.1996.03890250052009","article-title":"Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications","volume":"132","author":"Wasik","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1038\/sj.jid.5700122_bb0155","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/eji.1830200412","article-title":"Interleukin 2 receptor targeted cytotoxicity. Receptor binding requirements for entry of a diptheria toxin-related interleukin 2 receptor fusion protein into cells","volume":"20","author":"Waters","year":"1990","journal-title":"Eur J Immunol"},{"key":"10.1038\/sj.jid.5700122_bb0160","first-page":"354","article-title":"EORTC Classification for Primary Cutaneous Lymphomas: A Proposal From the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer","volume":"90","author":"Willemze","year":"1997","journal-title":"Blood"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X15327950?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X15327950?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,12]],"date-time":"2020-04-12T02:43:15Z","timestamp":1586659395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X15327950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["S0022202X15327950"],"URL":"https:\/\/doi.org\/10.1038\/sj.jid.5700122","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,3]]}}}